Introduction: Stomach cancer (SC) is a highly lethal neoplasm, ranking as the fourth leading cause of cancer deaths worldwide. Its etiopathogenesis is multifactorial, involving modifiable factors—such as poor diet, smoking, and Helicobacter pylori infection—and non-modifiable factors—such as advanced age and male sex. In Brazil, Law No. 12,732/2012 ensures the initiation of oncological treatment within the Unified Health System (UHS) within 60 days after diagnosis, encompassing chemotherapy, radiotherapy, and surgical approaches, according to clinical conduct.Objectives: To analyze the evolution of malignant stomach neoplasm diagnoses in the state of Pará between 2013 and 2023. Methods: This is an ecological, descriptive, and retrospective study of the temporal evolution of diagnoses for Malignant Stomach Neoplasm (ICD-10: C16) in the state of Pará from 2013 to 2023. Data were obtained from the Oncology Treatment Monitoring Panel (Oncology-Panel/DATASUS), using the variables: sex, age group, staging, establishment, and therapeutic modality. Data collection took place in April 2025. Results: Between 2013 and 2023, a total of 2,556 cases of SC were recorded, with the highest incidence in 2021 (424; 16.6%). Men were more affected (1,699; 66.5%) compared to women (857; 33.5%). Concerning age group, there was a concentration among elderly individuals aged 60 to 64 years (402; 15.7%). Regarding diagnostic staging, stage 4 was the most frequent (681; 26.6%), as well as indeterminate classifications such as “not applicable” and “ignored” (941; 36.8%). The majority of diagnoses were established at the Ophir Loyola Hospital (1,439; 56.3%) and the João de Barros Barreto University Hospital (577; 22.6%), both reference oncology centers. As for therapeutic modality, chemotherapy was the most used treatment (1,474; 57.7%), while radiotherapy was the least used (120; 4.7%), in addition to cases classified as “no information” (533; 20.9%). Conclusion: This temporal analysis revealed heterogeneity in the number of diagnoses, with a peak in 2021. Most cases involved men and elderly individuals aged 60 to 64 years, frequently diagnosed at advanced or undefined stages. Chemotherapy (57.7%) was the main therapeutic modality, possibly reflecting limited surgical or radiotherapeutic options. These findings indicate the need to strengthen public policies aimed at prevention and treatment planning, considering sex- and age-specific profiles.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
